Olmesartán/Amlodipino/Hidroclorotiazida Viso Farmacéutica (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan medoxil, amlodipine, hydrochlorothiazide, the active ingredients in Olmesartán/Amlodipino/Hidroclorotiazida Viso Farmacéutica, is a combination antihypertensive presented as a tablet for oral use. It treats hypertension, often in patients who require more than one mechanism to control blood pressure. GNH USA supplies Olmesartán/Amlodipino/Hidroclorotiazida Viso Farmacéutica as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olmesartán/Amlodipino/Hidroclorotiazida Viso Farmacéutica as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan/Amlodipine/Hydrochlorothiazide is a fixed‑dose combination that acts on several pathways involved in blood‑pressure regulation.

- Hypertension: provides additive blood‑pressure reduction when monotherapy is insufficient. - High‑risk cardiovascular patients: helps achieve target blood pressure to lower risk of stroke and myocardial infarction. - Patients with fluid retention: adds diuretic effect to improve volume control alongside vasodilation and renin‑angiotensin blockade.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Headache: mild to moderate intensity. - Peripheral edema: swelling of ankles or feet. - Dizziness or light‑headedness: especially after the first doses. - Flushing: transient warmth or redness. - Fatigue: general tiredness. - Increased urination: due to the diuretic component.

Serious or Rare Side Effects: - Angio‑edema: swelling of lips, tongue or airway. - Severe hypotension: marked drop in blood pressure causing fainting. - Electrolyte disturbances: significant changes in potassium or sodium levels. - Acute kidney injury: sudden decline in renal function. - Hepatic dysfunction: abnormal liver enzymes. - Blood dyscrasias: rare blood‑cell abnormalities.

Before initiating therapy, clinicians should evaluate patient history and monitor relevant parameters.

- Renal impairment: adjust dose or avoid if severe. - Hepatic disease: use with caution; monitor liver function. - Electrolyte imbalance: check potassium and sodium levels regularly. - Pregnancy: contraindicated in the second and third trimesters; avoid unless clearly needed. - Elderly patients: start at lower dose and titrate slowly. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and light.

Olmesartan/Amlodipine/Hydrochlorothiazide may interact with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Potassium‑saving diuretics or supplements: risk of hyperkalaemia. - Strong CYP3A4 inhibitors (e.g., clarithromycin): increase amlodipine levels. - NSAIDs (high dose): may blunt antihypertensive effect and affect renal function.

Moderate Interactions (Monitor Closely): - Lithium: may increase serum lithium concentrations. - Other antihypertensives: additive blood‑pressure lowering effect. - Antidiabetic agents: may enhance glucose‑lowering effect. - Alcohol: can increase dizziness and hypotension risk.